DSIP dosage in published experiments
The route, species and exact substance change from paper to paper. There is no established human dosing standard.
The human study amount
The 1981 insomnia experiment administered synthetic DSIP intravenously at 25 nmol/kg body weight to six middle-aged people with chronic insomnia. Nanomoles describe an amount of molecules; the kilogram denominator means the research amount was adjusted to body weight.
The human ACTH experiment also used 25 nmol/kg intravenously. A recurring amount in old studies is useful bibliographic information. It has never supplied an approved personal dose or an established protocol for treating insomnia.
The research lacks the human pharmacokinetic and safety data needed to justify such a step. The small sleep trial also reported slight arousal before the later sleep-promoting effect, which complicates assumptions about timing.
DSIP peptide dosage across animal studies
The protocols differ considerably. In adult male rats after focal stroke, investigators administered 120 micrograms/kg per intranasal dose, with 8 doses around the experimental stroke. The rat hypoxia experiment studied 120 micrograms/kg by injection. In metaphit-induced epilepsy in rats, DSIP was studied at 0.1–1 mg/kg, with the greatest effect at 1 mg/kg.
The female SHR mouse longevity study used a DSIP-containing preparation at about 100 micrograms/kg, subcutaneously, in courses of 5 consecutive days each month. That schedule describes what the animal experiment did. It offers no human safety or longevity regimen.
An isolated amount carries surprisingly little meaning across this collection. A seizure model, a focal stroke and a mouse lifespan experiment each ask a different question. Changing the species, route and preparation changes the experiment as well.
The DSIP peptide nasal spray question
Interest in a nasal route often leads back to the rat stroke experiment. Intranasal DSIP improved motor recovery by day 7; the difference in infarct volume lacked statistical significance. The study tested rats after experimental focal stroke.
It did not validate a human nasal spray, establish human absorption or identify a safe personal amount. The gap defeats, for me, the suggestion of a ready-made treatment route. The human sleep evidence discussed here used intravenous administration in a study setting.
For the outcome itself, the stroke section includes the volume comparison.
Variable response and rapid breakdown
DSIP and its phosphorylated form showed an inverted bell-shaped response in a rat hypothermia experiment involving apomorphine: the smallest effective amount was 10 ng and the maximal effect occurred at 1 microgram. A larger amount did not reliably give a larger effect. This was a drug-induced temperature experiment in rats, with no direct bedtime rule to extract.
The 2006 review describes the wider difficulties of DSIP biology and altered forms. Animal plasma clearance work put the circulating half-life on the order of minutes; no validated human pharmacokinetic profile exists. Pharmacokinetics describes how a body handles a substance over time.
I want the exposure measurements alongside the outcome: how do route and effect fit together in a controlled experiment? The current record leaves that relationship too incomplete to turn this page of study amounts into personal instructions.